[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-ALDX":3,"homepage-market-summary":30,"stock-news-ALDX":172},{"ticker":4,"date":5,"profile":6,"quote":14},"ALDX","2026-10-01",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9},"Aldeyra Therapeutics, Inc.","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.","6","Lexington, MA",{"close":15,"open":16,"high":17,"low":18,"prev_close":19,"change":20,"percent_change":21,"volume":22,"transactions":23,"vwap":24,"high_52w":25,"low_52w":26,"avg_volume_52w":27,"range_52w_percent":28,"record_count":29},1.29,1.26,1.305,1.195,1.23,0.06,4.88,1156100.804616,3638,1.2509,16.7,1.07,643215.7404730093,1.4,3123,{"status":31,"indices":32,"watchlist":74,"sectors":97,"benchmarks":152},"success",[33,41,48,55,61,68],{"symbol":34,"name":35,"price":36,"change":37,"pct_change":38,"is_up":39,"sparkline":40,"date":5},"SPX","S&P 500",7666.45,14.91,0.19,true,"0.0,3.1 2.3,5.0 4.6,8.0 6.9,10.4 9.3,13.4 11.6,9.1 13.9,11.5 16.2,13.8 18.5,16.0 20.8,10.3 23.2,9.5 25.5,2.0 27.8,2.0 30.1,5.9 32.4,6.0 34.7,3.4 37.1,7.3 39.4,8.2 41.7,9.4 44.0,8.5",{"symbol":42,"name":43,"price":44,"change":45,"pct_change":46,"is_up":39,"sparkline":47,"date":5},"NDX","NASDAQ 100",30501.56,93.06,0.31,"0.0,11.8 2.3,11.3 4.6,11.6 6.9,12.2 9.3,14.7 11.6,12.6 13.9,14.5 16.2,16.0 18.5,15.9 20.8,12.0 23.2,10.5 25.5,4.0 27.8,2.0 30.1,4.0 32.4,4.0 34.7,3.0 37.1,5.6 39.4,5.1 41.7,4.5 44.0,3.8",{"symbol":49,"name":50,"price":51,"change":52,"pct_change":53,"is_up":39,"sparkline":54,"date":5},"DJI","DOW JONES",50927,21,0.04,"0.0,2.0 2.3,3.4 4.6,6.5 6.9,8.6 9.3,10.2 11.6,7.6 13.9,8.4 16.2,10.0 18.5,13.2 20.8,11.6 23.2,12.1 25.5,10.2 27.8,11.2 30.1,12.9 32.4,13.8 34.7,11.4 37.1,13.1 39.4,13.8 41.7,16.0 44.0,15.9",{"symbol":56,"name":57,"price":58,"change":59,"pct_change":53,"is_up":39,"sparkline":60,"date":5},"COMP","NASDAQ Composite",26871.6,10.53,"0.0,9.3 2.3,10.2 4.6,11.1 6.9,13.0 9.3,14.9 11.6,12.1 13.9,13.7 16.2,16.0 18.5,16.0 20.8,11.1 23.2,10.0 25.5,3.4 27.8,2.0 30.1,5.4 32.4,5.4 34.7,3.9 37.1,6.7 39.4,6.9 41.7,6.2 44.0,6.1",{"symbol":62,"name":63,"price":64,"change":65,"pct_change":66,"is_up":39,"sparkline":67,"date":5},"RUT","RUSSELL 2000",2790.2,11.3,0.41,"0.0,2.6 2.3,2.0 4.6,3.0 6.9,6.1 9.3,8.4 11.6,7.5 13.9,8.8 16.2,10.4 18.5,11.3 20.8,10.2 23.2,11.2 25.5,10.1 27.8,8.8 30.1,12.9 32.4,13.1 34.7,12.8 37.1,14.4 39.4,15.1 41.7,16.0 44.0,15.1",{"symbol":69,"name":70,"price":71,"change":72,"pct_change":46,"is_up":39,"sparkline":73,"date":5},"VIX","CBOE VIX",16.39,0.05,"0.0,15.6 2.3,14.8 4.6,10.2 6.9,7.3 9.3,2.0 11.6,9.7 13.9,4.9 16.2,4.5 18.5,2.5 20.8,11.3 23.2,13.7 25.5,13.5 27.8,16.0 30.1,12.3 32.4,10.4 34.7,13.5 37.1,8.8 39.4,8.9 41.7,7.8 44.0,7.6",[75,82,90],{"symbol":76,"name":77,"price":78,"change":79,"pct_change":80,"is_up":39,"sparkline":81,"date":5},"NVDA","NVIDIA Corp",230.86,2.48,1.09,"0.0,13.9 7.3,16.0 14.7,14.9 22.0,6.5 29.3,10.1 36.7,7.5 44.0,2.0",{"symbol":83,"name":84,"price":85,"change":86,"pct_change":87,"is_up":88,"sparkline":89,"date":5},"AAPL","Apple Inc",330.32,-2.7,-0.81,false,"0.0,6.9 7.3,8.2 14.7,2.0 22.0,5.2 29.3,16.0 36.7,11.7 44.0,14.9",{"symbol":91,"name":92,"price":93,"change":94,"pct_change":95,"is_up":88,"sparkline":96,"date":5},"TSLA","Tesla Inc",354.11,-0.7,-0.2,"0.0,2.0 7.3,3.1 14.7,6.1 22.0,13.6 29.3,16.0 36.7,15.0 44.0,15.3",[98,103,108,113,118,123,128,133,137,142,147],{"name":99,"etf":100,"change":101,"price":102,"is_up":39},"Technology","XLK",1.05,197.81,{"name":104,"etf":105,"change":106,"price":107,"is_up":39},"Financials","XLF",0.11,53.46,{"name":109,"etf":110,"change":111,"price":112,"is_up":88},"Healthcare","XLV",-1.32,166.2,{"name":114,"etf":115,"change":116,"price":117,"is_up":88},"Consumer Cycl","XLY",-0.03,108.81,{"name":119,"etf":120,"change":121,"price":122,"is_up":88},"Consumer Staples","XLP",-0.33,80.33,{"name":124,"etf":125,"change":126,"price":127,"is_up":39},"Energy","XLE",1.95,62.7,{"name":129,"etf":130,"change":131,"price":132,"is_up":39},"Industrials","XLI",0.99,168.64,{"name":134,"etf":135,"change":121,"price":136,"is_up":88},"Materials","XLB",48.54,{"name":138,"etf":139,"change":140,"price":141,"is_up":88},"Real Estate","XLRE",-0.56,40.68,{"name":143,"etf":144,"change":145,"price":146,"is_up":39},"Utilities","XLU",0.61,39.68,{"name":148,"etf":149,"change":150,"price":151,"is_up":88},"Comm Services","XLC",-0.93,109.94,[153,158,162,167],{"ticker":154,"name":155,"price":156,"change":157,"is_up":39},"SPY","SPDR S&P 500 ETF",763.99,0.18,{"ticker":159,"name":160,"price":161,"change":46,"is_up":39},"QQQ","Invesco QQQ Trust",742.03,{"ticker":163,"name":164,"price":165,"change":166,"is_up":39},"DIA","SPDR Dow Jones ETF",508.68,0.03,{"ticker":168,"name":169,"price":170,"change":171,"is_up":39},"IWM","iShares Russell 2000",279.06,0.42,{"ticker":4,"count":173,"articles":174},14,[175,181,187,193,199,205,211,217,223,229,234,240,246,251],{"title":176,"link":177,"pubDate":178,"description":179,"source":180},"After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuAFBVV95cUxPZW5mcGNKcDVoRFRMNjFmdXl1VkRSREgwbk5xX2VsQnBHbGEzdFZuREpVd1BRd0h5SmQtMnNiYXdvMGx2MmlOWkdxaVlBSnR2WmhjelVjU1F2UFBzMFZXVUs3djc1VDRYVFYxMEZsSS16LTMxUXZJclJud0ZRQ3p1MlFKZUVFTlpiZ1dwMGVBUGN5MUdURlZwNGtCODM5R1llWk9tcTdyQWFmOUZRYVYwTGhJMUZSS1FO?oc=5","Tue, 29 Sep 2026 11:00:00 GMT","After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. Stock Titan","Stock Titan",{"title":182,"link":183,"pubDate":184,"description":185,"source":186},"Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow (NASDAQ:ALDX) 2026-09-30 - Seeking Alpha","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMizwFBVV95cUxPbk9NQmtFQms0N3Rvdk1TcEwtMDBKUWM2eGJlT0M4bzhxb2pRdWVaRDdRekkzZnppNk54OGlETFM2UzM2TmxSR1lBRjZuX2VLNF9CMWxxd0pUTUlWQ01KTEpQV1pvRHYzOVBRTUEzTXY1TGZIR3V4eWRFU1FzbHdUd3VwLXNTUkxCNW1MZFlhd01SeFdEZTBkel84blhLellneGtMNXh2WHhWSjhnWFRURmJoc3gzcHRNVTcwLVlJN0NjQ1NXdU02SFlYenlQQkU?oc=5","Wed, 30 Sep 2026 08:02:11 GMT","Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow (NASDAQ:ALDX) 2026-09-30 Seeking Alpha","Seeking Alpha",{"title":188,"link":189,"pubDate":190,"description":191,"source":192},"ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - tradingview.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxOcHR6ZXFPaWtmTkZZbXdJYWphTGNVQ090VF9BVUY3Q19mcHNINmpRMGlhSDRweGtUTGJIenFMb2dxamJuYUdjQVZ3aVhCSHZOc2dheG04ZDBSVXJST3VEZVNRS1pmMWpUNGFERDd6S1pvN2tEM3p5ekZqZ043RjJsaUZCRkdkMTNRNHZqMGpLTkhROEJJc0ZuOU52YlhoU013T1JWOHJiX2lnSFhvbzU2VjRldng5R0NHNmFCcE9JUGgwdw?oc=5","Fri, 25 Sep 2026 15:02:00 GMT","ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal tradingview.com","tradingview.com",{"title":194,"link":195,"pubDate":196,"description":197,"source":198},"Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiTEFVX3lxTFBYRHhqV2duOFZmNEdmMTl6V2pCckhHY1NUWFlKZWttOWg4RENOZzNvNXJVcjFiR1BJN2EtdVBMc0tYZmZ6TmNvQ1MwQkQ?oc=5","Sat, 26 Sep 2026 00:43:00 GMT","Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ timothysykes.com","timothysykes.com",{"title":200,"link":201,"pubDate":202,"description":203,"source":204},"What's going on in today's after hours session - ChartMill","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMinAFBVV95cUxOQ2RHUlMwdks1b2d6MENYdXpIWnJzRGxxYjdEdUE3akg5R2NhS0lSWVIxRUVTelFza2s5RjhwTzFaanpfNHBMLTVUVjA2X3FDcTlzV2o4LVZLWWIxdS1QYXNkZDRVZ3dnbXlXRHVwLWJDdjNFREZyaWVzX0ZXRXYxOFBqSklVMTZlQlFpVlRwc3BDSW1kSklwRXZKbDY?oc=5","Tue, 29 Sep 2026 21:00:00 GMT","What's going on in today's after hours session ChartMill","ChartMill",{"title":206,"link":207,"pubDate":208,"description":209,"source":210},"ALDX Reiterated by BTIG -- Price Target Maintained at $9.00 - gurufocus.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMimAFBVV95cUxOUWdnb2FwWnZ3eDMydFROVndoeUh5cjltb2lyVkhROHQzQnp4Wm5YOUh5QjdVQmZSdU9iT21QTTRWRlZsWmNQUmFPQnBaeHlPWHZrSm4wSFJ0dldBVjVPb0NFQ3M1cEZEX2YyX2FrZW4zY0RkdFk2Q2MtRTNET2hDUXBySWwwcDY2VkppZ0dNTHlOTTNZd1hFOA?oc=5","Tue, 29 Sep 2026 17:25:37 GMT","ALDX Reiterated by BTIG -- Price Target Maintained at $9.00 gurufocus.com","gurufocus.com",{"title":212,"link":213,"pubDate":214,"description":215,"source":216},"Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL - benzinga.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiugFBVV95cUxQTjlQQ05GSDQwOTV1R2M4X2ZzME9GSkhxUXFoTjNMQXd5U3VILVZYMnZQa1dJUVhpdmFhVUZMbEhkTF9Uc3dkWmF5alZMTkZpTDhsYVFqeGFNeE8wWkpuUkdDN0JmcUJtR1EwLXpvRjNQSk5BUlB3Q1RrNGZyRW5GVnJleVFpdDZud3I0aDBKZkU0dFI0eFJUck1JQjJPTVVNcVpaWlJPVW4yMlh4UU84Ukh0dzNpRHUxcFE?oc=5","Tue, 29 Sep 2026 18:34:11 GMT","Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL benzinga.com","benzinga.com",{"title":218,"link":219,"pubDate":220,"description":221,"source":222},"H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target By Investing.com - Investing.com Nigeria","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivwFBVV95cUxNczI2aXlQSk9aVngzQW5ScGsxdTNLVGZOQ05zWmhHc3hzaDZ3Ml9PVVdoRnRnWjNVVTRfVTFsNEJxM1VUbkxsdDNqMGpRXzVlcC1wa0hhMVJZNHk2NGJlSWM5cjc0YmVubkFGTzdPVVE0clRfWFlwZ05CWFRsMFdFOUhiRVJ4NUpBdVRPQVFobTJNQXdrcEF2QUc5UjY1dGJBTHRRUjltc0RkTHdmMmNRclViMVpJOGdVQ1lOWVliMA?oc=5","Wed, 30 Sep 2026 13:23:48 GMT","H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target By Investing.com Investing.com Nigeria","Investing.com Nigeria",{"title":224,"link":225,"pubDate":226,"description":227,"source":228},"Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi5wFBVV95cUxQQXE1UTRZcHpqMEkwdnVtcmVxVzQ0VkxGT3B0c3JLelFKNkpxUmxyMllKQnBoSllYM0RseHlvTjcwa2tJM3FCeUpUQkM4RTBka20zUHNKMjRSZE9LanBhcUJ3RkxSMkE4ekxyYTc5eFp5ckpsRUVDTHJRMUV4ZHY0bWg0QWc1V19UTWRXRmpmWm02T2dLcC03cWh4M2M1aVlRTDg2a08wWGU1RjlRejF0TEFRVzVIREQycXh3MUJ2Y25va09VOHhjY0MtejB0ZkRjQTU3RlJiTUFBRWVzZ0E0M1ZGNmRqclE?oc=5","Tue, 29 Sep 2026 15:20:00 GMT","Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 The Globe and Mail","The Globe and Mail",{"title":230,"link":231,"pubDate":232,"description":233,"source":210},"ALDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 - gurufocus.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiqAFBVV95cUxNMW5ybTltaWlPb2c4d0laaHpyd0FqLW5GbHhCOVlJdWZVTUlIQXlDMkRHOWxWanFkRWoyU0ltMW9PWHdqRDRtV3FUOGNPU0hjOEswWnU5XzJOQkNhQlIwczZoZk1vcWtxRF8tNjVMaHhqelBQOTMzYU1FLTkxVlpfcm15em4yZlBBZUI4dWJLWHJPS05LU09GejJtdExRYkswcTVVbjJYZlk?oc=5","Wed, 30 Sep 2026 11:18:29 GMT","ALDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 gurufocus.com",{"title":235,"link":236,"pubDate":237,"description":238,"source":239},"Zacks Investment Research - גלובס","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiYkFVX3lxTFAtZDBRdXJwMHh4RHpUVWJwbHA4dkdHTXMycmtvRXBWSjE5NGsxX3g0eXNtUVd1TFBkaHhjSjhlYzFfeko3LXM3SGpWZVpWc0dRcjRjcDYzR1RuMWtzLUZSa3JR?oc=5","Wed, 23 Sep 2026 07:00:00 GMT","Zacks Investment Research גלובס","גלובס",{"title":241,"link":242,"pubDate":243,"description":244,"source":245},"Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline - es.tradingview.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxPbHA3dHdXa2ZzRm03RDc0WG1SWlRDaUMtcHJPV1R3d3JGd1luQng2b2JLWkRlbVZfdmdrWjZLUDVWclFVOGhXRHVWQ1F6bnBoRklHSzE5Tm1YeHk3Q0ExZ2szSmRfdFhGM0ZqcFliT0ZBZjZtU25wXzBiSDk4bEVYSlNuQ0twRUR0UTI0aUF5Zmc5eExWV1RwbVE4TjFKNUI1SEoxQ3NHd1BDV3h4bHp1QXRlQV9QczI2Z0Q4NXQtUzMwZw?oc=5","Tue, 29 Sep 2026 14:12:00 GMT","Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline es.tradingview.com","es.tradingview.com",{"title":247,"link":248,"pubDate":249,"description":250,"source":192},"Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU - tradingview.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxQdmpyM01jN0l4UW1NZWk1cWZSejZjRHJ1Z0lzQ0V0YWRLXzc4ZWlfblJpUTZaRFIwdlFhak5OU3hsWGlIekR6Nzd0TUppak5fNjV4MlJuVEdpR2hTbHdLSzF3Z253VERJdG0wZFVqb01UTW5UOFNvQzZaemtfeU4zbm1vemhhRHFad25xeW9Rc1VmVEdKNU9nYkJIbUNVTWxOc203RFJLVWJQNFVDZVJCcERzMHZGUWsyd1lVaXhhazltdw?oc=5","Mon, 21 Sep 2026 14:59:00 GMT","Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU tradingview.com",{"title":252,"link":253,"pubDate":254,"description":255,"source":256},"Live Aldeyra Therapeutics, Inc. (ALDX) Technical Analysis - Traders Union","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMib0FVX3lxTE51YkFMdVZtVXNhU1NRUkZLR2t2b1o1NUZyUVhZS1NSWVRsb2pqQ1B0LXZwN2hycVJIOUs1TzRzUlB6ZUJxcklXSnVmaGUybDlPb1hGTDV0d0JDUHdNRWt3N0hVLXJqaHVXWGRhZjBZcw?oc=5","Wed, 23 Sep 2026 22:00:33 GMT","Live Aldeyra Therapeutics, Inc. (ALDX) Technical Analysis Traders Union","Traders Union"]